Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XDd in Advanced Light-Chain Cardiac Amyloidosis
NCT07743957Phase 2Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jul 2026
- Primary completion
- Feb 2028
01
Overview
A Phase 2 trial of selinexor in light-chain cardiac amyloidosis (AL-CM), sponsored by Beijing An Zhen Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
light-chain cardiac amyloidosis (AL-CM)
Beyond the preview
Go deeper on NCT07743957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743957.